Literature DB >> 21193420

MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context.

Maria Kleppe1, Nicole Mentens, Thomas Tousseyn, Iwona Wlodarska, Jan Cools.   

Abstract

The mouse pro-B cell line Ba/F3 has gained major interest as a model system to investigate oncogenic tyrosine kinases and to determine the efficacy of kinase inhibitors. While Ba/F3 cells are suitable to study oncogenic kinases derived from various cell types, the signaling networks in Ba/F3 cells are B-cell specific. We have established a mouse CD4+CD8+ double positive T-cell line (named MOHITO, for MOuse Hematopoietic Interleukin-dependent cell line of T-cell Origin) that has many features of human T-cell acute lymphoblastic leukemia (Notch1 and Jak1 mutation, TCR rearrangement) and is dependent on interleukin-7. The MOHITO cell line can be transformed to cytokine independent proliferation by BCR-ABL1 or mutant JAK1. This mouse T-cell line is a novel model system to investigate protein signaling and inhibition in a T-cell specific context and is a valuable tool to study and verify oncogenic capacity of mutations in the kinome and phosphatome in T-cell malignancies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21193420      PMCID: PMC3084928          DOI: 10.3324/haematol.2010.035931

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  26 in total

1.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

2.  JAK1 mutation analysis in T-cell acute lymphoblastic leukemia cell lines.

Authors:  Michaël Porcu; Olga Gielen; Jan Cools; Kim De Keersmaecker
Journal:  Haematologica       Date:  2009-01-27       Impact factor: 9.941

3.  JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study.

Authors:  Vahid Asnafi; Sandrine Le Noir; Ludovic Lhermitte; Claude Gardin; Faézeh Legrand; Xavier Vallantin; Jean-Valère Malfuson; Norbert Ifrah; Hervé Dombret; Elizabeth Macintyre
Journal:  Br J Haematol       Date:  2009-09-18       Impact factor: 6.998

Review 4.  Lineage fate and intense debate: myths, models and mechanisms of CD4- versus CD8-lineage choice.

Authors:  Alfred Singer; Stanley Adoro; Jung-Hyun Park
Journal:  Nat Rev Immunol       Date:  2008-10       Impact factor: 53.106

5.  Inactivation of LEF1 in T-cell acute lymphoblastic leukemia.

Authors:  Alejandro Gutierrez; Takaomi Sanda; Wenxue Ma; Jianhua Zhang; Ruta Grebliunaite; Suzanne Dahlberg; Donna Neuberg; Alexei Protopopov; Stuart S Winter; Richard S Larson; Michael J Borowitz; Lewis B Silverman; Lynda Chin; Stephen P Hunger; Catriona Jamieson; Stephen E Sallan; A Thomas Look
Journal:  Blood       Date:  2010-02-01       Impact factor: 22.113

Review 6.  Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia.

Authors:  Clemens Grabher; Harald von Boehmer; A Thomas Look
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

Review 7.  Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.

Authors:  Teresa Palomero; Adolfo Ferrando
Journal:  Clin Lymphoma Myeloma       Date:  2009

Review 8.  NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia.

Authors:  P J Real; A A Ferrando
Journal:  Leukemia       Date:  2009-04-09       Impact factor: 11.528

9.  The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.

Authors:  S Li; R L Ilaria; R P Million; G Q Daley; R A Van Etten
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

10.  Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia.

Authors:  Elisabetta Flex; Valentina Petrangeli; Lorenzo Stella; Sabina Chiaretti; Tekla Hornakova; Laurent Knoops; Cristina Ariola; Valentina Fodale; Emmanuelle Clappier; Francesca Paoloni; Simone Martinelli; Alessandra Fragale; Massimo Sanchez; Simona Tavolaro; Monica Messina; Giovanni Cazzaniga; Andrea Camera; Giovanni Pizzolo; Assunta Tornesello; Marco Vignetti; Angela Battistini; Hélène Cavé; Bruce D Gelb; Jean-Christophe Renauld; Andrea Biondi; Stefan N Constantinescu; Robin Foà; Marco Tartaglia
Journal:  J Exp Med       Date:  2008-03-24       Impact factor: 14.307

View more
  8 in total

1.  Development of a siRNA and shRNA screening system based on a kinase fusion protein.

Authors:  Sofie Pieraets; Luk Cox; Olga Gielen; Jan Cools
Journal:  RNA       Date:  2012-04-26       Impact factor: 4.942

2.  Genetic and epigenetic studies offer new therapeutic options for the treatment of T-cell acute lymphoblastic leukemia.

Authors:  Jan Cools
Journal:  Haematologica       Date:  2012-03       Impact factor: 9.941

3.  Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma.

Authors:  Maria Kleppe; Thomas Tousseyn; Eva Geissinger; Zeynep Kalender Atak; Stein Aerts; Andreas Rosenwald; Iwona Wlodarska; Jan Cools
Journal:  Haematologica       Date:  2011-07-26       Impact factor: 9.941

4.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.

Authors:  Jinghui Zhang; Li Ding; Linda Holmfeldt; Gang Wu; Sue L Heatley; Debbie Payne-Turner; John Easton; Xiang Chen; Jianmin Wang; Michael Rusch; Charles Lu; Shann-Ching Chen; Lei Wei; J Racquel Collins-Underwood; Jing Ma; Kathryn G Roberts; Stanley B Pounds; Anatoly Ulyanov; Jared Becksfort; Pankaj Gupta; Robert Huether; Richard W Kriwacki; Matthew Parker; Daniel J McGoldrick; David Zhao; Daniel Alford; Stephen Espy; Kiran Chand Bobba; Guangchun Song; Deqing Pei; Cheng Cheng; Stefan Roberts; Michael I Barbato; Dario Campana; Elaine Coustan-Smith; Sheila A Shurtleff; Susana C Raimondi; Maria Kleppe; Jan Cools; Kristin A Shimano; Michelle L Hermiston; Sergei Doulatov; Kolja Eppert; Elisa Laurenti; Faiyaz Notta; John E Dick; Giuseppe Basso; Stephen P Hunger; Mignon L Loh; Meenakshi Devidas; Brent Wood; Stuart Winter; Kimberley P Dunsmore; Robert S Fulton; Lucinda L Fulton; Xin Hong; Christopher C Harris; David J Dooling; Kerri Ochoa; Kimberly J Johnson; John C Obenauer; William E Evans; Ching-Hon Pui; Clayton W Naeve; Timothy J Ley; Elaine R Mardis; Richard K Wilson; James R Downing; Charles G Mullighan
Journal:  Nature       Date:  2012-01-11       Impact factor: 49.962

5.  The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia.

Authors:  Joni Van der Meulen; Viraj Sanghvi; Konstantinos Mavrakis; Kaat Durinck; Fang Fang; Filip Matthijssens; Pieter Rondou; Monica Rosen; Tim Pieters; Peter Vandenberghe; Eric Delabesse; Tim Lammens; Barbara De Moerloose; Björn Menten; Nadine Van Roy; Bruno Verhasselt; Bruce Poppe; Yves Benoit; Tom Taghon; Ari M Melnick; Frank Speleman; Hans-Guido Wendel; Pieter Van Vlierberghe
Journal:  Blood       Date:  2014-10-15       Impact factor: 22.113

6.  Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia.

Authors:  A Schwarzer; H Holtmann; M Brugman; J Meyer; C Schauerte; J Zuber; D Steinemann; B Schlegelberger; Z Li; C Baum
Journal:  Oncogene       Date:  2014-09-22       Impact factor: 9.867

7.  Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.

Authors:  Nicole Kucine; Sachie Marubayashi; Neha Bhagwat; Efthymia Papalexi; Priya Koppikar; Marta Sanchez Martin; Lauren Dong; Marty S Tallman; Elisabeth Paietta; Kai Wang; Jie He; Doron Lipson; Phil Stephens; Vince Miller; Jacob M Rowe; Julie Teruya-Feldstein; Charles G Mullighan; Adolfo A Ferrando; Andrei Krivtsov; Scott Armstrong; Laura Leung; Stefan O Ochiana; Gabriela Chiosis; Ross L Levine; Maria Kleppe
Journal:  Blood       Date:  2015-10-06       Impact factor: 22.113

8.  Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system.

Authors:  S Bornschein; S Demeyer; R Stirparo; O Gielen; C Vicente; E Geerdens; B Ghesquière; S Aerts; J Cools; C E de Bock
Journal:  Leukemia       Date:  2017-11-20       Impact factor: 11.528

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.